Condiciones de salud que Platycodon puede ayudar a apoyar.
Preclinical studies show Platycodon root extract suppresses mast cell-derived allergic mediators including IgE, prostaglandin D2, leukotriene C4, and IL-6. Platycodin D inhibits Th2 cytokine production via the NF-κB pathway in allergic asthma models. Evidence remains predominantly in vitro and animal-based with no completed human RCTs specifically for respiratory allergy.
Platycodin D and total platycosides exhibit radical-scavenging activity against DPPH and ABTS free radicals, with platycodin D showing the greatest TOSC value against peroxyl radicals among the isolated saponins. Antioxidant activity is confirmed in vitro and in animal models of oxidative stress.
Platycodon root and platycodin D have demonstrated anti-asthmatic effects in animal models by reducing Th2 cytokines (IL-4, IL-5, IL-6, IL-13), eosinophilia, and NF-κB pathway activation in lung tissue. Platycodon is listed in traditional texts for bronchial asthma. Preclinical evidence is mechanistically strong; human trials are absent.
Platycodon grandiflorum has been described as a traditional prescription to lower blood pressure in ethnopharmacological literature. Preclinical studies in spontaneously hypertensive rats demonstrate antihypertensive effects via angiotensin II/IGF-IIR pathway modulation. Animal evidence is more robust than human evidence.
Multiple animal studies show Platycodon saponins and polysaccharides reduce fasting blood glucose, improve glucose tolerance, and modulate adipokines in diabetic and high-fat-diet models. One human RCT (NCT04023864) tested a PG extract in obese adults. Preclinical mechanistic data are strong; human evidence is limited.
Platycodon root is one of the best-documented herbs for bronchial conditions in both traditional and modern pharmacological literature. Platycodin saponins enhance mucociliary clearance, reduce bronchial inflammation via TLR4/NF-κB pathways, and have been studied in chronic bronchitis models. Traditional use across Chinese, Korean, and Japanese medicine is extensive.
Platycodon saponins, fermented extracts, and polysaccharides consistently reduce total cholesterol and LDL while increasing HDL in high-fat-diet and diabetic animal models. Platycodin D inhibits lipase and intestinal fat absorption genes. A human clinical trial (NCT04023864) reported blood lipid-lowering effects in obese patients.
Platycodin D and related saponins from PG root suppress pro-inflammatory NF-κB, MAPK, PI3K/AKT, and TLR4/MyD88 signaling pathways and reduce cytokines including TNF-α, IL-1β, and IL-6 across multiple in vitro and animal studies. These anti-inflammatory actions underpin many of PG's other documented effects.
Platycodon has been studied in cigarette smoke-induced chronic bronchitis models relevant to COPD pathology. PG inhibits TLR4/MyD88/NF-κB-driven airway inflammation and reduces mucus hypersecretion and structural airway changes. Evidence is from preclinical studies; no human COPD trials exist.
Platycodon root extracts and saponins have demonstrated efficacy in reducing atopic dermatitis-like skin lesions in NC/Nga mouse models, suppressing IgE, Th2 cytokines (IL-4, IgG1), and inflammatory cell infiltration. Both topical and oral routes have been studied. No human RCT for dermatitis with PG alone has been published.
Platycodon polysaccharides have been shown to modulate gut microbiota composition in animal models, increasing beneficial bacteria such as Akkermansia, improving intestinal barrier integrity, and reducing dysbiosis associated with high-fat diet and immunosuppression. These effects are linked to broader metabolic and immune outcomes.
Platycodon root extract has demonstrated anti-obesity effects in multiple preclinical models and one human RCT. Platycodin D inhibits lipase and intracellular triglyceride accumulation, while PG polysaccharides reduce body weight and adiposity in high-fat-diet mice. A double-blind RCT in 108 Korean overweight adults showed significant reduction in body fat mass and abdominal fat.
Platycodon exhibits cardiovascular protective effects in preclinical studies, including protection of vascular endothelial cells from oxidized LDL injury, antihypertensive effects in spontaneously hypertensive rats, and reduction of dyslipidemia. Saponin and ethyl acetate fractions are the primary active components studied.
Platycodon root and its polysaccharide fractions have been shown to improve insulin resistance in high-fat-diet and NAFLD animal models, reducing hepatic insulin resistance and improving AMPK-mediated lipid metabolism. Adipokine modulation including adiponectin and leptin normalization has also been demonstrated.
Platycodon root has documented hepatoprotective effects across multiple animal models, including protection against endotoxin-induced acute liver injury, high-fat-diet-induced NAFLD, and chemically induced liver fibrosis. Key markers including ALT, AST, and hepatic lipid accumulation are improved by PG fractions.
Platycodon grandiflorus (balloon flower root, jie geng) has been used in TCM and Korean herbal medicine for over 2,000 years to treat cough, phlegm, and bronchitis. Its saponins (platycodin D) demonstrate expectorant, anti-inflammatory, and immunomodulatory effects in vitro and in animal asthma models, including NF-κB pathway suppression.
Platycodon's expectorant and mucolytic properties are among its most pharmacologically confirmed effects. Platycodin saponins enhance tracheal mucociliary movement and stimulate respiratory secretions that aid phlegm clearance. This effect is recognized in the Chinese Pharmacopoeia and supported by modern pharmacological evidence.
Platycodon saponins and fermented PG extracts consistently reduce serum triglyceride levels in high-fat-diet animal models. One human RCT demonstrated lipid-lowering effects in obese adults. Platycodin D inhibits intracellular triglyceride accumulation and intestinal fat absorption.
Platycodon grandiflorum exhibits documented antiviral activity against multiple respiratory viruses including SARS-CoV, blocking viral replication stages and activating host immune defenses including T cells and macrophages. A 2025 systematic review of PubMed/Web of Science literature confirmed broad-spectrum antiviral effects.
Platycodon root has been used in TCM for over a millennium specifically to treat lung abscesses and drain pus. The Chinese Pharmacopoeia and classical texts such as the Compendium of Materia Medica document this use. Modern pharmacological work identifies anti-inflammatory and antibacterial saponins as plausible active components, but controlled human trials for abscess treatment are absent.
Platycodon grandiflorus (balloon flower root, Jie Geng) is a foundational herb in Traditional Chinese Medicine and Korean medicine for bronchial congestion, cough, and bronchitis, classified as an expectorant in the Chinese and Korean Pharmacopoeias. The 2025 Frontiers in Pharmacology systematic review on chronic bronchitis identifies its polysaccharides and platycodin D as suppressing mucin expression in CB models.
Platycodon root is a foundational ingredient in traditional Northeast Asian formulas for colds and flu, addressing cough, sore throat, and phlegm. Korean and Japanese traditional medicines have used it for acute respiratory infections for centuries. Modern antiviral preclinical evidence provides biological plausibility, but dedicated human RCTs for cold and flu are lacking.
TCM classical texts record Platycodon root for chest pain and lung conditions consistent with pleurisy presentations, including lung abscesses with chest pain and dyspnea. The Han Dynasty use of PG for dyspnea and chest congestion is documented. No modern clinical or experimental studies specifically address pleurisy.
Platycodon root is widely employed in TCM, Kampo, and Korean traditional medicine seasonal formulas for upper respiratory tract support during autumn and winter, addressing cough, phlegm, and throat irritation. This use is documented in pharmacopoeias across Northeast Asia, though no seasonal-specific clinical trials exist.
Platycodon is used in TCM formulas addressing nasal congestion and upper respiratory stuffiness, leveraging its expectorant, anti-inflammatory, and 'lung-opening' properties. Traditional formulas such as those for acute rhinitis and sinusitis commonly include Jiegeng. Clinical trial evidence specific to sinus and nasal congestion is not available.
Relieving sore throat is one of Platycodon root's primary indications in the Chinese Pharmacopoeia and in TCM, Kampo, and Korean traditional medicine. The herb has been used for pharyngitis, tonsillitis, and throat pain for over 2000 years. Modern data show anti-inflammatory and antibacterial activity that is mechanistically plausible, but human clinical trials are lacking.
Platycodon (Platycodon grandiflorum, Balloon Flower) is a classical TCM herb specifically prescribed for sore throat, pharyngitis, and tonsillitis as part of the Sho-saiko-to-ka-kikyo-sekko formula studied for tonsillitis. It is listed in multiple authoritative TCM texts as a primary herb for throat and lung conditions. Platycodin D saponins demonstrate anti-inflammatory and mucolytic effects.
The Compendium of Materia Medica (Ming Dynasty, 1578 CE) records Platycodon root for oral ulcers. TCM texts also note use for dysentery, which involved intestinal ulceration. No modern clinical or preclinical studies specifically target gastric or oral ulcer healing with PG.
Platycodon grandiflorum (balloon flower) root is used in TCM and Korean traditional medicine for cough, sore throat, and phlegm in upper respiratory conditions. Its triterpenoid saponins (platycodin D) have expectorant, anti-inflammatory, and antiviral properties. It appears in multiple classical URTI formulas.
Volver